Form 4: Pacira BioSciences SVP Lauren Riker Reports Stock Transactions

Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, reports acquisition of stock units and sale of common stock under a pre-arranged 10b5-1 trading plan.

Summary

• On June 12, 2024, Lauren Riker, Senior Vice President of Finance at Pacira BioSciences, acquired 21,360 shares of common stock.
• These shares were acquired as restricted stock units that vest in four equal annual installments beginning on June 3, 2025, contingent upon continuous service with the issuer.
• On the same day, Riker sold 3,970 shares of common stock at a weighted average price of $28.72 per share, with prices ranging from $28.33 to $29.32.
• The sales were executed under a Rule 10b5-1 trading plan previously adopted by Riker.
• Following these transactions, Riker beneficially owns 42,045.335 shares directly and 38,075.335 shares directly after the sale.

Sentiment

Score: 6

Explanation: Neutral sentiment as the document reports routine stock transactions by a company executive. The use of a 10b5-1 plan suggests a proactive approach to compliance.

Positives

• The acquisition of restricted stock units aligns Riker's interests with the long-term performance of Pacira BioSciences.
• The use of a pre-arranged 10b5-1 trading plan for stock sales demonstrates transparency and avoids concerns about insider trading.

Future Outlook

The reported transactions do not provide specific forward-looking statements, but the vesting of restricted stock units suggests an expectation of continued service by the reporting person.

Industry Context

Form 4 filings are a routine part of corporate governance, providing transparency into the transactions of company insiders. The use of 10b5-1 plans is a common practice to manage insider trading risks.

Stakeholder Impact

• The transactions provide transparency to shareholders regarding insider activity.
• The vesting of restricted stock units incentivizes the executive to contribute to the company's success.

Key Dates